Navigation Links
New England Journal of Medicine hails new skin cancer drug as 'greatest advance yet'
Date:6/13/2012

ssistant Professor in TGen's Integrated Cancer Genomics Division.

This Phase 2 study provided the efficacy data for vismodegib that led to its approval by the U.S. Food and Drug Administration (FDA) on Jan. 30, 2012.

"As a result of a strong collaboration between the Valley institutions, clinical development of this new medication, from the first clinical trial to the FDA approval, was led by the Valley researchers," said Dr. Sekulic, M.D and Ph.D., whose study found that vismodegib shrank advanced basal cell carcinoma tumors in 43 percent of patients with locally advanced disease and in 30 percent of patients whose disease spread to other organs.

The drug blocks the Hedgehog signaling pathway and was approved for treatment of locally advanced and metastatic basal cell carcinomas. Additional research noted encouraging results for patients with inherited genetic susceptibility for development of large numbers of BCC tumors, known as basal cell nevus syndrome.

"The availability of vismodegib and similar medications will really change the way we treat the patients with advanced forms of BCC, who had very limited options to date. In addition, this drug will likely offer a life-changing treatment for patients with basal cell nevus syndrome. It is possible that the drug may also be of benefit in treatment of earlier stages of BCC, and this is currently being evaluated in several clinical trials," Dr. Sekulic said.

"It is a landmark day for patients with basal cell carcinoma and all those involved in their care," said the NEJM editorial. However the editors cautioned that additional study of Hedgehog pathway inhibitors like vismodegib warrant further study so a larger number of patients may benefit.

FDA approval in five years is a remarkable achievement because clinical trials typically progress through three phases and can take up to 15 years to successfully complete, according to Mark Slater, Ph.D., Vice President of
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Red Tide Likely in New England This Season, Experts Warn
2. Elsevier, SVS announce 2013 launch of Journal of Vascular Surgery: Venous and Lymphatic Disorders
3. NAMS journal Menopause reflects on the WHI 10 years later
4. Reactions to HIV drug have autoimmune cause, reports AIDS journal
5. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
6. Journals and pharma collaborate on new recommendations
7. Model for breast cancer rehab featured in supplement to ACS journal, Cancer
8. Piramal imaging to present data at Society for Nuclear Medicine Annual Meeting
9. Surgeon General receives 2012 Distinguished Public Service Award from internal medicine physicians
10. Nanomedicines promise fewer side effects in treating cancer
11. Applied nanobiomedicine: Exploiting nanoparticles to hunt for hidden cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... Utah (PRWEB) May 18, 2013 ... on insurance agents’ role in Marketplaces . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... Health and Human Services (HHS) recently released a ...
(Date:5/18/2013)... After working diligently for months and putting in a ... integration of the fitment specs for the redesigned 2012 Hyundai ... the automobile market with its extraordinary features and unique combination ... the latest entry in the size it up ... year 2013. , Aptly suiting its name, 2012 Hyundai ...
(Date:5/18/2013)... Although obesity is associated with an increased ... and esophageal adenocarcinoma, a type of esophageal cancer, is ... reported on Cancer.gov, last reviewed in January 2012, ... as those of normal and healthy weight to develop ... esophageal cancer is not well understood, it is now ...
(Date:5/18/2013)... May 18, 2013 Show And Go Training, ... various different training systems that is all about is getting ... the attention of http://ShowAndGoTrainingReview.com ’s Stan Stevenson, prompting ... is a unique “four phase system” designed to make you ... of time spent working out in the gym. The training ...
(Date:5/18/2013)... May 18, 2013 Losing weight remains to ... among the horde of new weight loss products available in ... about. Recent studies about this newest weight loss supplement prove ... body shape. , Garcinia Cambogia is a sub-tropical fruit that ... Eating the fruit can suppress a person’s appetite, while it ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2
... Drugs,(NYSE: LDG ) announced its flu immunization program at ... of those communities remain,healthy and combat the annual flu season. ... meet its customers, needs. -- Longs Drugs will be ... beginning in October through the middle of November. ...
... for Trading on OTC Bulletin Board Shortly -, ... Board: EMED) announced today that the U.S. Securities and,Exchange ... by Card Activation Technologies, Inc. As a result of,the ... its Form 211 application, as filed with the NASD, ...
... 24 With the cold and,flu season now upon ... to washing their hands on a regular basis because,according ... hands is,the single most important measure people can take ... "Studies have shown that 40 percent of women and ...
... Cancer Center at Jefferson and Thomas Jefferson University Hospital ... implant radiation-emitting seeds in prostate cancer patients. While the ... based in The Netherlands, is only being used for ... help with the actual placement of the seeds. To ...
... Hope",charity auction, hosted by Pittsburgh Steeler Alan Faneca and his ... - 11 p.m. at the Jerome,Bettis Grille 36 on the ... the evening off with an autograph session from 7-8,p.m. Throughout ... of sports,memorabilia will take place. Local sportscaster Bob Pompeani will ...
... PRINCETON, N.J., Sept. 23 Covance Inc. (NYSE:,CVD) today ... Life Sciences,Conference on September 24 at 3:30 pm ET. ... http://www.covance.com . In order to register and,download any ... Covance, with headquarters in Princeton, New Jersey, is one ...
Cached Medicine News:Health News:Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season 2Health News:Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season 3Health News:MedCom USA's Subsidiary Card Activation Technologies, Inc.'s SB2 Registration Declared Effective by SEC 2Health News:Clean Hands are Key to Fighting Cold, Flu Germs 2Health News:Jefferson radiation oncologists use real-time system to plant 'seeds' against cancer 2Health News:Super Bowl Champion, Pro Bowler and Pittsburgh Steeler Alan Faneca to Host Sixth Annual 'Bid for Hope' Auction 2
(Date:5/17/2013)...  Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... UBS Global Healthcare Conference in New York ... at 11 a.m. Eastern Time. To listen to the ... the Investor Relations section of the Company,s Web site at ... days after the event. About Orexigen® Therapeutics ...
(Date:5/17/2013)... DIEGO and CAMBRIDGE, Mass., May 17, 2013 /PRNewswire/ ... that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) ... Court for the District of Massachusetts ... its officers violated the Securities Exchange Act of 1934 ... 1, 2013 (the "Class Period"). (Logo: ...
(Date:5/17/2013)... Ill. , May 17, 2013  Sony Biotechnology ... Sony SP6800 Spectral Analyzer (SP6800).  Sony will be exhibiting ... which will be held at the San ... Diego, California , from May 20 - 22.  ... second analytical system, incorporating commercial audio-visual technologies into new ...
Breaking Medicine Technology:Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2
... PLYMOUTH MEETING, Pa., June 9 Genaera,Corporation ... presentation by Genaera,scientists of preclinical data on ... treatment of type 2 diabetes and obesity, ... Diabetes Association in San,Francisco, California., The ...
... SUNNYVALE, Calif., June 9 Pharmacyclics, Inc.,(Nasdaq: ... study evaluating,PCI-32765, an orally available, selective inhibitor of ... an established animal model,for rheumatoid arthritis (RA). The ... Societies (FOCIS) meeting being held this,week in Boston, ...
Cached Medicine Technology:Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association 2Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association 3Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association 4Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 2Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 3Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 4
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: